These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23995268)

  • 1. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.
    Einolf HJ; Chen L; Fahmi OA; Gibson CR; Obach RS; Shebley M; Silva J; Sinz MW; Unadkat JD; Zhang L; Zhao P
    Clin Pharmacol Ther; 2014 Feb; 95(2):179-88. PubMed ID: 23995268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
    Waters NJ
    Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models.
    Ramsden D; Fullenwider CL
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):467-482. PubMed ID: 35344159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
    Mao J; Fan P; Wong S; Wang J; Ismaili MHA; Dean B; Hop CECA; Wright M; Chen Y
    Pharm Res; 2017 Nov; 34(11):2403-2414. PubMed ID: 28815392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.
    Sun Y; Chothe PP; Sager JE; Tsao H; Moore A; Laitinen L; Hariparsad N
    Drug Metab Dispos; 2017 Jun; 45(6):692-705. PubMed ID: 28336578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes.
    Zhang JG; Ho T; Callendrello AL; Clark RJ; Santone EA; Kinsman S; Xiao D; Fox LG; Einolf HJ; Stresser DM
    Drug Metab Dispos; 2014 Sep; 42(9):1379-91. PubMed ID: 24924386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
    Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
    Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
    Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro.
    Fahmi OA; Maurer TS; Kish M; Cardenas E; Boldt S; Nettleton D
    Drug Metab Dispos; 2008 Aug; 36(8):1698-708. PubMed ID: 18490437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
    Varma MV; Lin J; Bi YA; Rotter CJ; Fahmi OA; Lam JL; El-Kattan AF; Goosen TC; Lai Y
    Drug Metab Dispos; 2013 May; 41(5):966-74. PubMed ID: 23393219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
    Halladay JS; Wong S; Khojasteh SC; Grepper S
    J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
    Templeton IE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 Oct; 39(10):1921-9. PubMed ID: 21771933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
    Dong JQ; Gosset JR; Fahmi OA; Lin Z; Chabot JR; Terra SG; Le V; Chidsey K; Nouri P; Kim A; Buckbinder L; Kalgutkar AS
    Drug Metab Dispos; 2017 May; 45(5):501-511. PubMed ID: 28254951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
    Shou M; Hayashi M; Pan Y; Xu Y; Morrissey K; Xu L; Skiles GL
    Drug Metab Dispos; 2008 Nov; 36(11):2355-70. PubMed ID: 18669588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.